Clinical trials: Patients Without Targetable Driver Mutations
Advanced Stage NSCLC, Second-line Treatment
Efficacy and Safety of High-Dose Rate Brachytherapy With Immunotherapy and Chemotherapy as Second-Line Treatment for Advanced Non-Small Cell Lung Cancer
This is a single-center, retrospective, propensity score-matched study exploring the efficacy and safety of high-dose rate (HDR) brachytherapy combined with immune checkpoint inhibitors (ICIs) and chemotherapy as a second-line…
- Conditions
- Advanced Stage NSCLC, Second-line Treatment, Patients Without Targetable Driver Mutations
- Trial name
- HIBIC-NSCLC (NCT06518018)
- Testing
- HDR brachytherapy (30Gy single fraction), Immunotherapy
- Where
- China
- Volunteers
- 80 people
- Sponsor
- The First People's Hospital of Neijiang